Key Points
- To update consensus guidelines concerning the epidemiology, clinical impact, diagnostic criteria, testing utility, and therapeutic management of cardiovascular autonomic neuropathy in diabetes.
- Convened by the Cardiovascular Autonomic Neuropathy Subcommittee of the Toronto Consensus Panel on Diabetic Neuropathy to review clinical evidence and establish standardized guidelines.
- Defined diagnostic criteria and clinical staging protocols using cardiovagal autonomic reflex testing and orthostatic blood pressure evaluations.
- Confirmed cardiovascular autonomic neuropathy affects approximately 20% of diabetic individuals and increases up to 65% with advanced age and diabetes duration, serving as a potent risk marker for cardiovascular morbidity and mortality.
- Diagnostic criteria establish early CAN via one abnormal cardiovagal test result, confirmed CAN via at least two abnormal cardiovagal results, and severe CAN via the concurrent presence of orthostatic hypotension.
- Intensive glycemic control effectively prevents CAN development in type 1 diabetes, but evidence remains insufficient to recommend most disease-specific therapeutic interventions or verify screening cost-effectiveness.
Structured PICO
PPopulationPatients with diabetes (type 1 and type 2) at risk for or with Cardiovascular Autonomic Neuropathy (CAN)
IInterventionCardiovascular Autonomic Neuropathy (CAN) testing and management
This consensus statement provides updated guidelines on the diagnosis, staging, and clinical relevance of cardiovascular autonomic neuropathy in patients with diabetes.
Limitations
- Evidence on the cost-effectiveness of CAN testing is lacking
- Recommendations cannot be made for most therapeutic approaches to CAN apart from intensive glycaemic control in type 1 diabetes